Halozyme Therapeutics, Inc. $HALO Shares Purchased by Intech Investment Management LLC

Intech Investment Management LLC raised its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 46.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 148,667 shares of the biopharmaceutical company’s stock after acquiring an additional 46,850 shares during the period. Intech Investment Management LLC’s holdings in Halozyme Therapeutics were worth $10,903,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of HALO. Root Financial Partners LLC bought a new stake in shares of Halozyme Therapeutics during the third quarter valued at about $25,000. Richardson Financial Services Inc. grew its position in Halozyme Therapeutics by 87.6% in the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 198 shares in the last quarter. Clearstead Advisors LLC increased its stake in Halozyme Therapeutics by 107.7% during the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 265 shares during the period. Newbridge Financial Services Group Inc. bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth about $32,000. Finally, Employees Retirement System of Texas acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $34,000. Institutional investors own 97.79% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on HALO. The Goldman Sachs Group reissued a “sell” rating and set a $56.00 target price on shares of Halozyme Therapeutics in a report on Thursday, December 4th. Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 21st. Weiss Ratings lowered Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a report on Tuesday. Citizens Jmp raised their target price on Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a research note on Tuesday, November 4th. Finally, TD Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Six investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $78.56.

Insider Activity

In other news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total value of $1,522,400.00. Following the transaction, the chief executive officer directly owned 708,719 shares of the company’s stock, valued at $53,947,690.28. This trade represents a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the completion of the sale, the director owned 40,123 shares of the company’s stock, valued at approximately $2,818,640.75. This trade represents a 4.75% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 49,398 shares of company stock valued at $3,650,592. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $69.22 on Friday. The stock’s fifty day simple moving average is $72.58 and its 200 day simple moving average is $70.59. The stock has a market capitalization of $8.17 billion, a price-to-earnings ratio of 27.80, a PEG ratio of 0.28 and a beta of 0.97. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89. Halozyme Therapeutics, Inc. has a 52-week low of $47.50 and a 52-week high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $1.92 by ($2.16). The company had revenue of $451.77 million for the quarter, compared to analysts’ expectations of $446.13 million. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The company’s revenue for the quarter was up 51.6% on a year-over-year basis. During the same period in the prior year, the company earned $1.26 earnings per share. As a group, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.